Intellia Therapeutics Inc.

09/16/2021 | Press release | Distributed by Public on 09/16/2021 05:34

Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid[...]